727 related articles for article (PubMed ID: 23051752)
1. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Landsberg J; Kohlmeyer J; Renn M; Bald T; Rogava M; Cron M; Fatho M; Lennerz V; Wölfel T; Hölzel M; Tüting T
Nature; 2012 Oct; 490(7420):412-6. PubMed ID: 23051752
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.
Mehta A; Kim YJ; Robert L; Tsoi J; Comin-Anduix B; Berent-Maoz B; Cochran AJ; Economou JS; Tumeh PC; Puig-Saus C; Ribas A
Cancer Discov; 2018 Aug; 8(8):935-943. PubMed ID: 29899062
[TBL] [Abstract][Full Text] [Related]
3. Cancer therapy: Tumours switch to resist.
Ribas A; Tumeh PC
Nature; 2012 Oct; 490(7420):347-8. PubMed ID: 23051745
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
5. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
6. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
[TBL] [Abstract][Full Text] [Related]
7. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
McKenzie JA; Mbofung RM; Malu S; Zhang M; Ashkin E; Devi S; Williams L; Tieu T; Peng W; Pradeep S; Xu C; Zorro Manrique S; Liu C; Huang L; Chen Y; Forget MA; Haymaker C; Bernatchez C; Satani N; Muller F; Roszik J; Kalra A; Heffernan T; Sood A; Hu J; Amaria R; Davis RE; Hwu P
J Natl Cancer Inst; 2018 Jul; 110(7):777-786. PubMed ID: 29267866
[TBL] [Abstract][Full Text] [Related]
9. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
10. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
11. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
12. The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells.
Mengoni M; Braun AD; Gaffal E; Tüting T
Int J Cancer; 2020 Nov; 147(10):2902-2913. PubMed ID: 32790916
[TBL] [Abstract][Full Text] [Related]
13. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens.
Saleh FH; Crotty KA; Hersey P; Menzies SW; Rahman W
J Pathol; 2003 Jul; 200(3):383-95. PubMed ID: 12845635
[TBL] [Abstract][Full Text] [Related]
14. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma.
Effern M; Glodde N; Braun M; Liebing J; Boll HN; Yong M; Bawden E; Hinze D; van den Boorn-Konijnenberg D; Daoud M; Aymans P; Landsberg J; Smyth MJ; Flatz L; Tüting T; Bald T; Gebhardt T; Hölzel M
Immunity; 2020 Sep; 53(3):564-580.e9. PubMed ID: 32750334
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?
Auphan-Anezin N; Verdeil G; Grange M; Soudja SM; Wehbe M; Buferne M; Mas A; Schmitt-Verhulst AM
Pigment Cell Melanoma Res; 2013 Mar; 26(2):167-75. PubMed ID: 23217139
[TBL] [Abstract][Full Text] [Related]
16. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
[TBL] [Abstract][Full Text] [Related]
18. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.
Reinhardt J; Landsberg J; Schmid-Burgk JL; Ramis BB; Bald T; Glodde N; Lopez-Ramos D; Young A; Ngiow SF; Nettersheim D; Schorle H; Quast T; Kolanus W; Schadendorf D; Long GV; Madore J; Scolyer RA; Ribas A; Smyth MJ; Tumeh PC; Tüting T; Hölzel M
Cancer Res; 2017 Sep; 77(17):4697-4709. PubMed ID: 28652246
[TBL] [Abstract][Full Text] [Related]
19. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
20. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
